Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Selina Pi

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Medrxiv : the Preprint Server for Health Sciences|May 9, 2025
Calculating epidemiological outcomes from simulated longitudinal dataSelina Pi, Jeremy D Goldhaber-Fiebert, Fernando Alarid-Escudero
AMIA ... Annual Symposium Proceedings. AMIA Symposium|January 15, 2024
Using Case Mix Index within Diagnosis-Related Groups to Evaluate Variation in Hospitalization Costs at a Large Academic Medical CenterSelina Pi, Jonathan Masterson, Stephen P Ma, et al.
Pharmacoeconomics|January 23, 2026
Discrete-Event Simulation Modeling Framework for Cancer Interventions and Population Health in R (DESCIPHR): An Open-Source PipelineSelina Pi, Carolyn M Rutter, Carlos Pineda-Antunez, et al.
Medrxiv : the Preprint Server for Health Sciences|June 4, 2025
Discrete-Event Simulation Model for Cancer Interventions and Population Health in R (DESCIPHR): An Open-Source PipelineSelina Pi, Carolyn M Rutter, Carlos Pineda-Antunez, et al.
Clinical Genitourinary Cancer|April 22, 2023
Impact of Therapy Management on Axitinib-Related Adverse Events in Patients With Advanced Renal Cell Carcinoma Receiving First-Line Axitinib + Checkpoint InhibitorYousef Zakharia, Lynn Huynh, Shawn Du, et al.
Journal of Managed Care & Specialty Pharmacy|November 29, 2024
Health care costs among patients with relapsed/refractory multiple myeloma treated with ixazomib or daratumumab in combination with lenalidomide and dexamethasone in the United StatesSikander Ailawadhi, Mu Cheng, Maral DerSarkissian, et al.
Gastro Hep Advances|June 10, 2025
Economic Burden of Patients With Chronic Idiopathic Constipation in the USA Before and After Prucalopride InitiationPaul Feuerstadt, Mei Lu, Emi Terasawa, et al.
Clinical and Translational Gastroenterology|February 15, 2024
Clinical Outcomes Before and After Prucalopride Treatment: An Observational Study in Patients With Chronic Idiopathic Constipation in the United StatesAnthony Lembo, Brooks D Cash, Mei Lu, et al.
Journal of Managed Care & Specialty Pharmacy|September 25, 2024
A real-world study of persistence and adherence to prescription medications in patients with chronic idiopathic constipation in the United StatesBrooks D Cash, Mei Lu, Anthony Lembo, et al.
Journal of Managed Care & Specialty Pharmacy|September 30, 2023
Comparison of health care costs and resource utilization for commonly used proteasome inhibitor-immunomodulatory drug-based triplet regimens for the management of patients with relapsed/refractory multiple myeloma in the United StatesLarysa Sanchez, Ajai Chari, Mu Cheng, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Medrxiv : the Preprint Server for Health Sciences|May 9, 2025
Calculating epidemiological outcomes from simulated longitudinal dataSelina Pi, Jeremy D Goldhaber-Fiebert, Fernando Alarid-Escudero
AMIA ... Annual Symposium Proceedings. AMIA Symposium|January 15, 2024
Using Case Mix Index within Diagnosis-Related Groups to Evaluate Variation in Hospitalization Costs at a Large Academic Medical CenterSelina Pi, Jonathan Masterson, Stephen P Ma, et al.
Pharmacoeconomics|January 23, 2026
Discrete-Event Simulation Modeling Framework for Cancer Interventions and Population Health in R (DESCIPHR): An Open-Source PipelineSelina Pi, Carolyn M Rutter, Carlos Pineda-Antunez, et al.
Medrxiv : the Preprint Server for Health Sciences|June 4, 2025
Discrete-Event Simulation Model for Cancer Interventions and Population Health in R (DESCIPHR): An Open-Source PipelineSelina Pi, Carolyn M Rutter, Carlos Pineda-Antunez, et al.
Clinical Genitourinary Cancer|April 22, 2023
Impact of Therapy Management on Axitinib-Related Adverse Events in Patients With Advanced Renal Cell Carcinoma Receiving First-Line Axitinib + Checkpoint InhibitorYousef Zakharia, Lynn Huynh, Shawn Du, et al.
Journal of Managed Care & Specialty Pharmacy|November 29, 2024
Health care costs among patients with relapsed/refractory multiple myeloma treated with ixazomib or daratumumab in combination with lenalidomide and dexamethasone in the United StatesSikander Ailawadhi, Mu Cheng, Maral DerSarkissian, et al.
Gastro Hep Advances|June 10, 2025
Economic Burden of Patients With Chronic Idiopathic Constipation in the USA Before and After Prucalopride InitiationPaul Feuerstadt, Mei Lu, Emi Terasawa, et al.
Clinical and Translational Gastroenterology|February 15, 2024
Clinical Outcomes Before and After Prucalopride Treatment: An Observational Study in Patients With Chronic Idiopathic Constipation in the United StatesAnthony Lembo, Brooks D Cash, Mei Lu, et al.
Journal of Managed Care & Specialty Pharmacy|September 25, 2024
A real-world study of persistence and adherence to prescription medications in patients with chronic idiopathic constipation in the United StatesBrooks D Cash, Mei Lu, Anthony Lembo, et al.
Journal of Managed Care & Specialty Pharmacy|September 30, 2023
Comparison of health care costs and resource utilization for commonly used proteasome inhibitor-immunomodulatory drug-based triplet regimens for the management of patients with relapsed/refractory multiple myeloma in the United StatesLarysa Sanchez, Ajai Chari, Mu Cheng, et al.
Pageof 1